Eyetech, Inc.
http://www.eyetech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyetech, Inc.
Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.
Stock Watch: Beware The Halo Effect Of Biopharma Leaders
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
Financings Of The Fortnight: Corporate Venture Plays Increased Role In Series A Financings
More than one-quarter of biopharma or diagnostic start-ups that raised A rounds in the past 18 months had participation by one or more corporate venture arms. Plus news on recent financings by Esperion Therapeutics, XO1, PTC Therapeutics and Valeant.
Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice